atai Beckley (formed from atai Life Sciences' combination with Beckley Psytech) develops psychedelic-based therapeutics for treatment-resistant depression and mental health conditions.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 63 | New buy | 81,911 | $431,671 | 0.0% |
| Ancora | 40 | Added +13% | 1,293 | $6,814 | 0.0% |
| Louis Bacon / Moore | 53 | Holds (flat) | 952,380 | $5,019,043 | 0.1% |
| Ruane Cunniff / Sequoia Fund | 75 | Holds (flat) | 42,112 | $221,930 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.